CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection.
Adult
Aged
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Asymptomatic Infections
CD4-Positive T-Lymphocytes
/ immunology
Capsid Proteins
/ immunology
Cohort Studies
Dengue Virus
/ chemistry
Epitopes, T-Lymphocyte
/ chemistry
Female
HLA-D Antigens
/ genetics
Humans
Immunodominant Epitopes
/ immunology
Male
Middle Aged
Peptide Library
RNA, Viral
/ blood
Viral Envelope Proteins
/ immunology
West Nile Fever
/ immunology
West Nile virus
/ chemistry
Yellow fever virus
/ chemistry
Zika Virus
/ chemistry
CD4 T cell
West Nile patients
West Nile virus
epitope
flavivirus
immunodominance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
accepted:
07
01
2020
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
20
2
2021
Statut:
epublish
Résumé
West Nile (WN) virus infection of humans is frequently asymptomatic, but can also lead to WN fever or neuroinvasive disease. CD4 T cells and B cells are critical in the defense against WN virus, and neutralizing antibodies, which are directed against the viral glycoprotein E, are an accepted correlate of protection. For the efficient production of these antibodies, B cells interact directly with CD4 helper T cells that recognize peptides from E or the two other structural proteins (capsid-C and membrane-prM/M) of the virus. However, the specific protein sites yielding such helper epitopes remain unknown. Here, we explored the CD4 T cell response in humans after WN virus infection using a comprehensive library of overlapping peptides covering all three structural proteins. By measuring T cell responses in 29 individuals with either WN virus disease or asymptomatic infection, we showed that CD4 T cells focus on peptides in specific structural elements of C and at the exposed surface of the pre- and postfusion forms of the E protein. Our data indicate that these immunodominant epitopes are recognized in the context of multiple different HLA molecules. Furthermore, we observed that immunodominant antigen regions are structurally conserved and similarly targeted in other mosquito-borne flaviviruses, including dengue, yellow fever, and Zika viruses. Together, these findings indicate a strong impact of virion protein structure on epitope selection and antigenicity, which is an important issue to consider in future vaccine design.
Identifiants
pubmed: 32038660
doi: 10.3389/fimmu.2020.00016
pmc: PMC6989424
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Capsid Proteins
0
Epitopes, T-Lymphocyte
0
HLA-D Antigens
0
Immunodominant Epitopes
0
Peptide Library
0
RNA, Viral
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Subventions
Organisme : Austrian Science Fund FWF
ID : P 29881
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 29928
Pays : Austria
Informations de copyright
Copyright © 2020 Koblischke, Spitzer, Florian, Aberle, Malafa, Fae, Cassaniti, Jungbauer, Knapp, Laferl, Fischer, Baldanti, Stiasny, Heinz and Aberle.
Références
J Virol. 1997 Nov;71(11):8475-81
pubmed: 9343204
J Virol. 2005 May;79(9):5665-75
pubmed: 15827181
Curr Opin Immunol. 2015 Jun;34:9-15
pubmed: 25576665
J Immunol. 2007 Jun 15;178(12):7890-901
pubmed: 17548627
PLoS One. 2016 Nov 3;11(11):e0165952
pubmed: 27812212
J Theor Biol. 2000 Apr 7;203(3):189-201
pubmed: 10716904
Viral Immunol. 2017 Sep;30(7):479-489
pubmed: 28614011
J Infect Dis. 2010 Jan 1;201(1):2-4
pubmed: 19961306
J Virol. 2017 Feb 14;91(5):
pubmed: 27974563
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Sci Rep. 2017 Aug 21;7(1):8907
pubmed: 28827760
Protein Sci. 2001 Jul;10(7):1470-3
pubmed: 11420449
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4587-92
pubmed: 11287644
Methods Mol Biol. 2012;857:231-57
pubmed: 22323224
Nat Rev Immunol. 2003 Aug;3(8):621-9
pubmed: 12974477
Eur J Immunol. 1989 Dec;19(12):2237-42
pubmed: 2481588
HLA. 2019 Feb;93(2-3):89-96
pubmed: 30488584
J Travel Med. 2018 Jan 1;25(1):
pubmed: 30289526
Nature. 2005 Sep 29;437(7059):764-9
pubmed: 16193056
J Exp Med. 2016 Jun 27;213(7):1331-52
pubmed: 27242166
J Immunol. 2003 Oct 15;171(8):4140-8
pubmed: 14530336
Nat Med. 2015 Oct;21(10):1216-22
pubmed: 26413780
NPJ Vaccines. 2019 Sep 6;4:38
pubmed: 31508246
J Immunol. 2012 May 1;188(9):4235-48
pubmed: 22467652
J Virol. 2006 Dec;80(24):12060-9
pubmed: 17035323
PLoS One. 2015 Oct 14;10(10):e0140545
pubmed: 26465323
Genome Med. 2015 Nov 20;7:119
pubmed: 26589500
BMC Bioinformatics. 2011 Jun 17;12:241
pubmed: 21679477
Viruses. 2019 Sep 05;11(9):
pubmed: 31491885
J Biol Chem. 2001 Nov 9;276(45):41913-20
pubmed: 11551929
J Virol. 2008 Feb;82(3):1238-48
pubmed: 18057238
J Clin Invest. 2009 Nov;119(11):3266-77
pubmed: 19855131
J Immunol Methods. 2016 May;432:72-81
pubmed: 26891811
EMBO J. 1986 Apr;5(4):823-6
pubmed: 3709526
Immunol Rev. 2008 Oct;225:212-25
pubmed: 18837784
J Virol. 2012 Feb;86(4):2337-46
pubmed: 22156523
J Virol. 2006 Nov;80(22):11000-8
pubmed: 16943291
Nature. 2016 Nov 10;539(7628):314
pubmed: 27626374
Vaccine. 2009 Nov 23;27(50):7021-6
pubmed: 19789092
PLoS One. 2018 Oct 31;13(10):e0205557
pubmed: 30379846
J Infect Dis. 2016 Oct 1;214(7):1117-24
pubmed: 27443615
Euro Surveill. 2018 Oct;23(43):
pubmed: 30376913
J Virol. 2013 Mar;87(5):2693-706
pubmed: 23255803
J Immunol. 2010 Jul 15;185(2):943-55
pubmed: 20554959
J Clin Virol. 2018 Nov;108:126-131
pubmed: 30312909
Science. 2016 Apr 22;352(6284):467-70
pubmed: 27033547
Cell Host Microbe. 2008 Sep 11;4(3):229-38
pubmed: 18779049
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6986-91
pubmed: 12759475
Amino Acids. 2011 Nov;41(5):1159-63
pubmed: 19882217
J Immunol. 2015 Jun 15;194(12):6164-6176
pubmed: 25948811
J Immunol. 2008 Dec 15;181(12):8568-75
pubmed: 19050276
PLoS Pathog. 2016 Jan 21;12(1):e1005375
pubmed: 26795118
Virol J. 2018 Nov 26;15(1):183
pubmed: 30477514
J Clin Invest. 2004 Apr;113(8):1102-7
pubmed: 15085186
Nat Commun. 2017 Apr 26;8(1):14
pubmed: 28446752
Tissue Antigens. 2003 Oct;62(4):296-307
pubmed: 12974796
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3414-9
pubmed: 14993605
Euro Surveill. 2013 Oct 24;18(43):
pubmed: 24176619
J Virol. 2014 Jul;88(14):7828-42
pubmed: 24789782
J Virol. 2013 Jan;87(2):818-28
pubmed: 23115296
Virology. 2015 May;479-480:498-507
pubmed: 25866377
Eur J Immunol. 2008 May;38(5):1231-7
pubmed: 18398933
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5
pubmed: 20956322
Mol Immunol. 2007 Feb;44(6):1159-68
pubmed: 16893568
J Clin Virol. 2006 Jul;36(3):177-82
pubmed: 16675298
Immunol Res. 2011 Dec;51(2-3):237-48
pubmed: 22101673
Immunogenetics. 2013 Oct;65(10):711-24
pubmed: 23900783
Nat Med. 2005 May;11(5):522-30
pubmed: 15852016
BMC Immunol. 2017 Jun 21;18(Suppl 1):20
pubmed: 28681704
Nature. 1995 May 25;375(6529):291-8
pubmed: 7753193
Front Immunol. 2018 Sep 11;9:2083
pubmed: 30254648
J Virol. 1995 Feb;69(2):695-700
pubmed: 7529335
PLoS One. 2011;6(8):e22948
pubmed: 21829673
Structure. 2004 Jul;12(7):1157-63
pubmed: 15242592
Curr Top Microbiol Immunol. 2008;317:125-53
pubmed: 17990792